| Literature DB >> 27475643 |
Jean B Nachega1,2,3, Olatunji Adetokunboh4, Olalekan A Uthman4,5, Amy W Knowlton6, Frederick L Altice7, Mauro Schechter8, Omar Galárraga9, Elvin Geng10, Karl Peltzer11,12,13, Larry W Chang6, Gilles Van Cutsem14, Shabbar S Jaffar15, Nathan Ford16, Claude A Mellins17, Robert H Remien18, Edward J Mills19.
Abstract
Little is known about the effect of community versus health facility-based interventions to improve and sustain antiretroviral therapy (ART) adherence, virologic suppression, and retention in care among HIV-infected individuals in low- and middle-income countries (LMICs). We systematically searched four electronic databases for all available randomized controlled trials (RCTs) and comparative cohort studies in LMICs comparing community versus health facility-based interventions. Relative risks (RRs) for pre-defined adherence, treatment engagement (linkage and retention in care), and relevant clinical outcomes were pooled using random effect models. Eleven cohort studies and eleven RCTs (N = 97,657) were included. Meta-analysis of the included RCTs comparing community- versus health facility-based interventions found comparable outcomes in terms of ART adherence (RR = 1.02, 95 % CI 0.99 to 1.04), virologic suppression (RR = 1.00, 95 % CI 0.98 to 1.03), and all-cause mortality (RR = 0.93, 95 % CI 0.73 to 1.18). The result of pooled analysis from the RCTs (RR = 1.03, 95 % CI 1.01 to 1.06) and cohort studies (RR = 1.09, 95 % CI 1.03 to 1.15) found that participants assigned to community-based interventions had statistically significantly higher rates of treatment engagement. Two studies found community-based ART delivery model either cost-saving or cost-effective. Community- versus facility-based models of ART delivery resulted in at least comparable outcomes for clinically stable HIV-infected patients on treatment in LMICs and are likely to be cost-effective.Entities:
Keywords: ART; Adherence; Community; Interventions; LMIC; Retention
Mesh:
Substances:
Year: 2016 PMID: 27475643 PMCID: PMC5357578 DOI: 10.1007/s11904-016-0325-9
Source DB: PubMed Journal: Curr HIV/AIDS Rep ISSN: 1548-3568 Impact factor: 5.071